Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results

Giuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna, Borislav D. Dimitrov, Dick De Zeeuw, Darcy A. Hille, Shahnaz Shahinfar, George W. Carides, Barry M. Brenner

Research output: Contribution to journalArticlepeer-review

Abstract

Renin angiotensin system inhibitor therapy is seldom offered to individuals who have diabetes and advanced chronic kidney disease because of safety concerns. In this post hoc, secondary analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, angiotensin antagonism risk/benefit profile was assessed in 1513 individuals with type 2 diabetes and overt nephropathy. Incidence of ESRD, hospitalizations for heart failure, withdrawals for adverse events, and proteinuria during losartan or conventional treatment were compared within three tertiles of baseline serum creatinine concentration (highest, 2.1 to 3.6 mg/dl; middle, 1.6 to 2.0 mg/dl; lowest, 0.9 to 1.6 mg/dl). Losartan decreased the risk of ESRD by 24.6, 26.3, and 35.3% in highest, middle, and lowest tertiles, respectively. For every 100 patients with serum creatinine >2.0, 1.6 to 2.0, or

Original languageEnglish
Pages (from-to)3117-3125
Number of pages9
JournalJournal of the American Society of Nephrology
Volume15
Issue number12
DOIs
Publication statusPublished - Dec 2004

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results'. Together they form a unique fingerprint.

Cite this